Thermo Fisher Raises Outlook; Shares Surge 12%

Thermo Fisher Scientific reported second-quarter 2025 revenue of $10.85 billion, up 3%, and adjusted earnings of $5.36 per share, surpassing analyst expectations due to strong demand for laboratory products and operational improvements. The company raised the lower end of its annual profit forecast to $22.22 per share, citing an improved US-China tariff environment and cost management through its Practical Process Improvement Business System. Its laboratory products segment, which makes up over half of company sales, generated $6 billion and exceeded estimates. Shares surged as much as 12%—the largest single-day gain since 2008—although they remain below their all-time high. CFO Stephen Williamson announced he will retire effective March 2026, with Jim Meyer named as successor. Thermo Fisher also continues to pursue acquisitions and supply chain enhancements to support rising pharmaceutical and biotech demand.